Real-world first-line treatments and outcomes for HR+/HER2- advanced breast cancer in China

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a longitudinal, retrospective, non-interventional observational analysis using routinely collected electronic health records and secondary data from the National Anti-Tumor Drug Surveillance System (NATDSS). The study will include adults diagnosed with HR+/HER2- advanced or metastatic breast cancer who began first-line systemic therapy between January 1, 2024 and January 1, 2027. Analyses will describe real-world treatment patterns, clinical outcomes, and influential factors associated with outcomes, with particular attention to the uptake and performance of CDK4/6 inhibitors and recent entrants like ribociclib. No active interventions, randomization, or control groups will be involved.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Diagnosed with HR+/HER2- ABC:

   HR+ is defined as ER+ or PR+, and HER2+ is defined as immunohistochemistry 3+, or 2+ with positive in situ hybridization (amplification). Advanced or metastatic breast cancer is defined as having a documented inoperable clinical or pathological stage IIIB, IIIC, or IV, or the records indicating distant metastasis.
2. Initiation of 1L anti-cancer treatment between Jan. 1, 2024 and Jan. 1, 2027; Defined as having records of systemic anti-cancer treatment in disease course records or order records within 90 days after the initial diagnosis of ABC, and receiving the first dose between Jan. 1, 2024 and Jan. 1, 2027, as recorded in the NATDSS database.
3. Aged 18 years or older at the time of receiving the 1L treatment; Definition: The initiation date (index date) of 1L treatment is defined as the initiation date of systemic anti-cancer treatment for HR+/HER2- ABC first recorded in the database. Age will be preferentially calculated based on the date of birth (or year of birth) and the initiation date of 1L treatment in the database. If the birth information is not included in the database but shown in an "Age" field in the medical visit/hospitalization record associated with 1L treatment, this age field will be used as the basis for age.
4. At least 3 months of follow-up records after the initiation of 1L treatment. Defined as having at least one outpatient or inpatient medical visit record in the NATDSS at least 3 months after the index date.

Exclusion Criteria:

(1) Patients with any other concomitant invasive malignancies Defined as patients meeting any of the following conditions based on their diagnosis records in the cancer registry/medical database used for the study: 1. Within 5 years before the diagnosis of HR+/HER2- ABC, there is a diagnosis record of invasive malignancy other than breast cancer in the database (based on the International Classification of Diseases \[ICD\] diagnosis code or cancer registry code), and the diagnosis is not carcinoma in situ or benign/borderline tumor; 2. On the day of, or within 3 months after, the diagnosis of HR+/HER2- ABC, there is a new diagnosis record of invasive malignancy at another site (also based on the ICD diagnosis code or cancer registry code) indicating a concomitant active malignancy.

Where it's running

• Novartis Investigative SIte
  Bingjie, Beijing Municipality, China Recruiting

Study contacts

• Study coordinator: Novartis Pharmaceuticals
• Email: novartis.email@novartis.com
• Phone: +41613241111

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• BEBT-209 with fulvestrant for HR+/HER2- advanced or metastatic breast cancer after prior hormone therapy

  This trial will test whether adding the experimental oral drug BEBT-209 to fulvestrant helps women with HR+/HER2- advanced or metastatic breast cancer that progressed after prior endocrine therapy.

  Recruiting Phase 3 BeBetter Med Inc · Beijing, Beijing Municipality · NCT06998108

• Capivasertib with preventive care for rash and diarrhea in metastatic HR+/HER2- breast cancer

  This phase II trial tests whether antihistamine and loperamide prophylaxis can reduce rash and diarrhea in adults starting capivasertib with fulvestrant.

  Recruiting Phase 2 Yale University · New Haven, Connecticut · NCT07426822

• New oral medicine PF-08032562 for advanced or metastatic breast and colorectal cancer

  This trial will try an oral medicine called PF-08032562, given alone or with other cancer drugs, in adults with advanced or metastatic breast or colorectal cancer.

  Recruiting at 13 sites Phase 1 Pfizer · Duarte, California and 16 other locations · NCT07318805

• Disitamab Vedotin for treating hormone receptor positive, HER2-low metastatic breast cancer

  This study is testing a new drug called Disitamab Vedotin to see if it can help people with hormone receptor positive, HER2-low metastatic breast cancer who haven't responded to standard treatments.

  Recruiting at 3 sites Phase 3 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Guangzhou, Guangdong and 2 other locations · NCT05904964

• Treatment for premenopausal women with metastatic breast cancer

  This study is testing whether a new treatment combining talazoparib with atezolizumab works better than talazoparib alone for premenopausal women with a specific type of metastatic breast cancer.

  Recruiting Phase 2 Samsung Medical Center · Seoul, Gannam-gu · NCT04819243

• Dalpiciclib with an aromatase inhibitor and olmesartan as first-line therapy for HR+/HER2- advanced breast cancer

  This trial tests whether adding dalpiciclib and olmesartan to an aromatase inhibitor helps people with HR+/HER2- advanced breast cancer respond to first-line treatment.

  Recruiting Phase 2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07810088

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.